All stocks / SIGY
Sigyn Therapeutics, Inc. SIGY
Sigyn Therapeutics (SIGY): convertible notes mentioned in an 8-K in February 2026, a late 10-K notice in March 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.
Market listing
- Full name
- SIGYN THERAPEUTICS INC
- Market tier
- OTC Pink Limited
- Trading status
- Active
- Last trade
- Nov 16
News headlines
The financial report, and what it means
Annual figures to 2024-12-31- Net loss
- ($3,340,212)
It spends more than it earns
Under strainThe company lost $3.3 million in the year. It reported no sales.
- Cash and cash equivalents
- $12,144
- Net cash used in operating activities
- ($872,436)
The cash could run out soon
Under strainIt had $12,144 in the bank and used about $72,703 a month. At that pace the money lasts less than a month unless it borrows or sells more shares.
- Total assets
- $213,719
- Total liabilities
- $4,671,343
It owes more than it owns
Under strainEverything the company owns adds up to $213,719. Its debts and unpaid bills add up to $4.7 million. That is about $21.86 owed for every $1 owned.
What this adds up to
3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.
Signals
Filed NT 10-K on 2026-03-31: notice that a periodic report is late.
Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record
8-K filed 2026-02-20 mentions: convertible note.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
Estimated float about 1,605,377 shares as of 2025-11-14: 1,605,377 outstanding minus 0 held by 0 reporting insider(s).
Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record
Shares outstanding
Source: SEC filingsPrice chart
Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets
Recent filings
| 2026-07-16 | 15-12G | 15-12G |
| 2026-03-31 | NT 10-K | NT 10-K |
| 2026-02-20 | 8-K | 8-K |
| 2026-01-14 | SCHEDULE 13G/A |
Common questions about SIGY
Does SIGY file reports with the SEC?
Yes. Sigyn Therapeutics files with the SEC under company number 0001642159. The most recent filing we hold is a 15-12G dated 2026-07-16.
Source recordHow many SIGY shares are outstanding?
1,605,377 shares as of 2025-11-14, as reported to the SEC.
Source recordHas SIGY filed reports late?
Yes. In the last 12 months it filed 1 late-filing notice, most recently a NT 10-K on 2026-03-31. A notice means a report was not ready on time; check whether the report followed.
Source recordIs Sigyn Therapeutics making money?
The company lost $3.3 million in the year. It reported no sales. (Annual figures to 2024-12-31. Facts from the company's own report, not a recommendation.)
Source record